Copyright
©The Author(s) 2021.
World J Gastroenterol. Jan 7, 2021; 27(1): 69-79
Published online Jan 7, 2021. doi: 10.3748/wjg.v27.i1.69
Published online Jan 7, 2021. doi: 10.3748/wjg.v27.i1.69
Table 1 Baseline characteristics of patients who underwent endoscopic ultrasound-guided celiac plexus neurolysis [n (%), n = 58]
| Independent variables | Total number |
| Age in yr, range (mean) | 54–73 (67) |
| Gender, female/male | 25/33 |
| Symptom | |
| Abdominal pain concomitant with jaundice Tumor largest dimension in mm, range (mean) | 6 (10.3) |
| Ascites, slight or mild | 24–100 (44.3) |
| Tumor location | 4 (6.9) |
| Pancreatic head/neck | |
| Pancreatic body/tail | 18 (31.0) |
| Initial VAS score, range (mean) | 40 (69.0) |
| Tramadol use before EUS-CPN | 6-10 (8) |
| Dose in mg, range (mean) | 51 (87.9) |
| Ganglia visualized | 0-240 (40) |
| Invasion of celiac plexus | 42 (72.4) |
| Distant metastasis | 16 (27.6) |
| Injected alcohol dose in mL, range (mean) | 26 (44.8) |
| Procedure method | 5–20 (10) |
| Unilateral | |
| Bilateral | 33 (56.9) |
| Intra-procedural decrease in heart rate | 25 (43.1) |
| decrease of ≥ 5 beats for ≥ 10 s | |
| 48 (82.8) |
- Citation: Han CQ, Tang XL, Zhang Q, Nie C, Liu J, Ding Z. Predictors of pain response after endoscopic ultrasound-guided celiac plexus neurolysis for abdominal pain caused by pancreatic malignancy. World J Gastroenterol 2021; 27(1): 69-79
- URL: https://www.wjgnet.com/1007-9327/full/v27/i1/69.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i1.69